Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations NIS793 - TGFẞ1 inhibitor Study Indication Phase Patients Primary Outcome Measures NCT02947165 (CNIS793X2101) Solid tumors Phase 1 120 Incidence of DLTS, AES, SAEs and dose reductions / interruptions for NIS793 Incidence of DLTS, AES, SAES and dose reductions/interruptions for NIS793 in combination with PDR001 Arms Intervention NIS793 NIS793 + PDR001 Adult patients with advanced malignancies Target Patients Read-out Milesstone(s) Publication 2021 TBD 109 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation